Parametric Portfolio Associates LLC lifted its holdings in AveXis, Inc. (NASDAQ:AVXS) by 2.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,943 shares of the company’s stock after purchasing an additional 598 shares during the quarter. Parametric Portfolio Associates LLC owned 0.08% of AveXis worth $1,721,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in AVXS. UBS Asset Management Americas Inc. bought a new stake in shares of AveXis in the first quarter worth $297,000. American International Group Inc. lifted its position in shares of AveXis by 26.7% in the first quarter. American International Group Inc. now owns 3,521 shares of the company’s stock worth $268,000 after purchasing an additional 742 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of AveXis by 2.6% in the first quarter. Teachers Advisors LLC now owns 54,217 shares of the company’s stock worth $4,122,000 after purchasing an additional 1,387 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of AveXis by 11.7% in the first quarter. Vanguard Group Inc. now owns 1,194,809 shares of the company’s stock worth $90,841,000 after purchasing an additional 124,750 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of AveXis by 2.9% in the first quarter. Geode Capital Management LLC now owns 127,512 shares of the company’s stock worth $9,694,000 after purchasing an additional 3,575 shares in the last quarter. 94.84% of the stock is currently owned by institutional investors and hedge funds.

In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $101.46, for a total value of $1,521,900.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $97.25, for a total transaction of $173,105.00. Following the completion of the transaction, the vice president now owns 1,780 shares in the company, valued at $173,105. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,340 shares of company stock worth $3,559,683. Corporate insiders own 18.60% of the company’s stock.

AveXis, Inc. (NASDAQ:AVXS) opened at $95.79 on Friday. AveXis, Inc. has a fifty-two week low of $44.68 and a fifty-two week high of $108.27.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the business posted ($0.87) EPS. equities research analysts expect that AveXis, Inc. will post -5.55 earnings per share for the current fiscal year.

A number of analysts have recently commented on the stock. Sanford C. Bernstein assumed coverage on shares of AveXis in a research report on Thursday, July 27th. They issued an “outperform” rating and a $108.00 price objective on the stock. Royal Bank Of Canada restated a “hold” rating and set a $92.00 target price on shares of AveXis in a report on Thursday, November 2nd. Bank of America Corporation lowered their target price on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a report on Friday. Evercore ISI assumed coverage on shares of AveXis in a report on Wednesday, August 16th. They set an “outperform” rating and a $120.00 target price on the stock. Finally, Chardan Capital restated a “buy” rating and set a $130.00 target price (up from $102.50) on shares of AveXis in a report on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company’s stock. AveXis currently has an average rating of “Buy” and an average price target of $108.26.

TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/12/parametric-portfolio-associates-llc-increases-stake-in-avexis-inc-avxs.html.

AveXis Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.